Lexigen Pharmaceuticals Corp.

About Lexigen Pharmaceuticals Corp.

Lexigen Pharmaceuticals Corp. is a leader in the creative development of genetically engineered proteins. The strategy of Lexigen Pharmaceuticals Corp. is to develop unique treatments for cancer and other serious, life-threatening diseases, and at the same time to develop broad technology platforms that will lead to new therapies.
Lexigen has two novel immunocytokines in clinical development. These antibody-cytokine fusion proteins target the immune system to specific cell types. Lexigen is developing the immunocytokines as cancer treatments, and simultaneously developing the immunocytokine concept as a broad, proprietary technology base.
Lexigen is an associate of Merck KGaA, Darmstadt, Germany, a multi-national pharmaceutical company with over 30,000 employees and annual revenues of approximately eight billion dollars. Thus, Lexigen combines the flexibility and creativity of a star-up biotech environment, with the financial stability, global presence, and commercial expertise of a large pharmaceutical company.
Last Updated 9-21-01